• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    TMC Expands Executive Team

    Peli BioThermal Opens Cold Chain Network Station in Southern California
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Purolite Expands Bioprocessing Production Capacity with New U.S. Facility
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Peli BioThermal Opens Cold Chain Network Station in Southern California

    Biocair Partners with TrakCel to Improve Visibility in the Supply Chain

    SpectronRx, RLS Partner to Boost Radiopharmaceutical Pipeline and Supply Chain

    Serialization and the War on Counterfeit Drugs

    Traceability & 2D Barcodes
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    RK Pharma to Receive $200M Investment from PAG

    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease

    Almac Group Global Workforce Hits 7,000 Employees

    Amarna Therapeutics Names Henk Streefkerk CEO

    Trinity Life Sciences Names Leslie Orne CEO
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Regulatory Affairs: Accelerating Drug Development Timelines

    Berkshire Sterile Secures Over $230,000 in Training Grants

    Purification – A Bottleneck for Large-Scale Manufacturing of Oligonucleotide API?

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    INCOG BioPharma Services

    LOTTE BIOLOGICS

    Quotient Sciences

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    INCOG BioPharma Services

    LOTTE BIOLOGICS

    Quotient Sciences

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    FDA’s Emergency Use Authorizations

    Aggressive Action Taken to Combat COVID-19

    FDA’s Emergency Use Authorizations
    Chad Landmon and Drew Hillier of Axinn, Veltrop & Harkrider LLP
    Chad Landmon and Drew Hillier, Axinn, Veltrop & Harkrider LLP04.20.20
    As the world scrambles to combat the COVID-19 pandemic, the U.S. Food and Drug Administration (FDA) has been aggressively using its Emergency Use Authorization (EUA) process to facilitate getting medical products to healthcare workers and patients as quickly as possible. Following the declaration of a public health emergency by Health and Human Services (HHS) Secretary Alex Azar on February 4, 2020, FDA has issued nearly 70 EUAs for a variety of diagnostics, medical devices, and personal protective equipment directed to the coronavirus outbreak.  

    In diagnostics alone, FDA has worked with over 300 test developers interested in submitting EUAs, resulting in more than 30 EUAs. This unprecedented activity by FDA is likely to continue as the nation struggles to diagnose and treat those impacted by COVID-19. Companies who are developing treatments, diagnostics, personal protective equipment, and other medical products directed to the COVID-19 crisis should be mindful of FDA’s EUA process and consider obtaining an EUA when appropriate.  

    Summary of EUA Process
    Multiple legislative changes over the last decade to the Federal Food, Drug, and Cosmetic Act (FD&C Act) have granted the FDA Commissioner the ability to issue EUAs to authorize the marketing of unapproved medical products or unapproved uses of approved medical products to diagnose, treat, or prevent serious or life-threatening diseases or conditions. Before FDA can issue an EUA, however, an emergency declaration must first be made by the HHS Secretary, finding that one of our circumstances exist: 
     
    1.    a domestic emergency involving a heightened risk of attack with a chemical, biological, radiological, or nuclear (CBRN) agent;
    2.    a military emergency with a heightened risk of an attack with a CBRN agent on U.S. military forces;
    3.    a public health emergency affecting or with the significant potential to affect national security or the health and security of U.S. citizens living abroad, that involves a CBRN agent or related disease or condition; or
    4.    a material threat sufficient to affect national security or the health and security of U.S. citizens living abroad.

    Following the emergency declaration by the HHS Secretary, companies can request an EUA from FDA. According to FDA’s guidance on Emergency Use Authorization of Medical Products and Related Authorities (2017 Guidance), the following information should be included in an EUA request:

    •    Description of product and its intended use
    •    Description of the product’s FDA approval status
    •    The need for the product, including whether there are adequate, approved, and available alternatives
    •    Available safety and efficacy information, including, for example, any controlled clinical trials, in vitro testing, and/or clinical experience
    •    A discussion of risks and benefits, including: (a) measures taken to mitigate risk or optimize benefit; (b) limitations, uncertainty, and data gaps; (c) contraindications; and (d) actual and potential threats posed by CBRN agents that may be relevant.
    •    Information on chemistry, manufacturing and controls, and the sites of manufacture, including the current good manufacturing practices (CGMP) status of those sites
    •    Information on the quantity of product on-hand and surge manufacturing capabilities
    •    Information comparable to an FDA-approved package insert or instructions for use; drafts of Fact Sheets for health care professionals and recipients of the product; and a discussion of the feasibility of providing this information in an emergency  
    •    Information to support an extension of a label’s expiration date, if sought –and–
    •    Any right of reference to rely upon data submitted by others

    Given that FDA’s resources are taxed in responding to the emergency, companies seeking an EUA should reach out to FDA before filing a request to ensure that the proper information is being submitted and that any special issues identified by FDA can be resolved. If required by the emergency and if FDA has adequate information, FDA can issue an EUA within hours or days of a request.  

    FDA’s Aggressive COVID-19 EUA Activity
    FDA has been aggressively reviewing and approving EUAs as it tackles the COVID-19 health emergency. The first COVID-related EUA was issued on February 4, 2020 for the Center for Disease Control and Prevention’s (CDC) Real-Time Reverse Transcriptase Diagnostic Panel.  Since that time, FDA has issued approximately 35 additional EUAs to test kit manufacturers and commercial laboratories for various in vitro diagnostic products. On March 31, 2020, FDA announced that it would provide authorization for certified high-complexity labs to use molecular-based laboratory tests that had been developed by the lab seeking authorization. 

    Approximately 15 laboratories have been granted a letter including them under the March 31 EUA.  FDA’s EUAs have also extended to personal protective equipment, including three EUAs for respirators and one EUA for face shields.  Other EUAs include:  four EUAS for reprocessing medical devices that provide decontamination or sterilization; one EUA for ventilation equipment; two EUAs for extracorporeal blood purification devices; one EUA for a therapeutic product, chloroquine, and three EUAs for other medical devices such as pumps and diaphragm pacing therapy systems.

    Given the unprecedented nature of the coronavirus pandemic and its impact on our nation, including shortages of critical supplies and diagnostics, the life sciences industry has been actively ramping up production and pursuing EUAs like never before. In coordinating such efforts with FDA, needed products have been rushed into our healthcare system to stem the tide of COVID-19.  Only time will tell how effective these efforts will be.


    Chad Landmon chairs Axinn, Veltrop & Harkrider LLP’s Intellectual Property and Food and Drug Administration Practice Groups and focuses his practice on patent litigation and counseling and food and drug law, with an emphasis on pharmaceuticals, biologics, medical devices, and human tissue products. He maintains a particular focus on patent trial work and FDA litigation, having served as a first chair trial lawyer on multiple cases and having litigated over 50 cases during the past 10 years alone, many of which have included products with billions of dollars in annual sales.

    Drew Hillier is an attorney at Axinn, Veltrop & Harkrider LLP. His experience includes representing manufacturers of pharmaceutical, biologic, and medical-device products in patent litigation, as well as related commercial and regulatory matters. Drew graduated first in his class from the University of Connecticut School of Law, where he was editor-in-chief of the law review. He clerked for U.S. District Judge Michael P. Shea in the District of Connecticut.
    Related Searches
    • patients
    • equipment
    • cGMP
    • Testing
    Suggested For You
    Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact
    GRAM, J&J Enter COVID-19 Vax Manufacturing Pact GRAM, J&J Enter COVID-19 Vax Manufacturing Pact
    J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax
    Hovione to Support Manufacture of Remdesivir for COVID-19 Hovione to Support Manufacture of Remdesivir for COVID-19
    ARCA Submits IND for AB201 in COVID-19 ARCA Submits IND for AB201 in COVID-19
    BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production
    Pharma Supply Chain Logistics & Potential COVID-19 Vaccines Pharma Supply Chain Logistics & Potential COVID-19 Vaccines
    Lilly, Amgen Enter Antibody Mfg. Pact for COVID-19 Therapies Lilly, Amgen Enter Antibody Mfg. Pact for COVID-19 Therapies
    FDA Clears IND Application for Vaxart Oral COVID-19 Vaccine FDA Clears IND Application for Vaxart Oral COVID-19 Vaccine
    Valneva Partners with UK Government for COVID-19 Vaccine Valneva Partners with UK Government for COVID-19 Vaccine
    Valneva, Dynavax Enter COVID-19 Vax Supply Pact  Valneva, Dynavax Enter COVID-19 Vax Supply Pact
    Novavax, Serum Institute of India Enter COVID-19 Vax Mfg. Pact Novavax, Serum Institute of India Enter COVID-19 Vax Mfg. Pact
    BioNTech to Receive German Federal Ministry Funding for COVID-19 Vax BioNTech to Receive German Federal Ministry Funding for COVID-19 Vax
    AstraZeneca Temporarily Halts COVID-19 Vax Trials of AZD1222 AstraZeneca Temporarily Halts COVID-19 Vax Trials of AZD1222
    iBio Advances COVID-19 Vaccine Candidate iBio Advances COVID-19 Vaccine Candidate

    Related Breaking News

    • Breaking News | cGMP Manufacture | Clinical Trial Materials | Fill/Finish | Industry News
      Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact

      Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact

      Par Sterile's Rochester facility began production of NVX-CoV2373 final drug product, with initial batches to be used in Novavax' Phase III trial.
      Contract Pharma Staff 09.25.20

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Fill/Finish | Industry News | Scale-up/Technology Transfer
      GRAM, J&J Enter COVID-19 Vax Manufacturing Pact

      GRAM, J&J Enter COVID-19 Vax Manufacturing Pact

      GRAM to provide advanced aseptic fill and finish services for supply of J&J’s SARS-CoV-2 vaccine candidate from its facility in Grand Rapids, MI.
      Contract Pharma Staff 09.25.20

    • Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Industry News
      J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax

      J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax

      Will enroll up to 60,000 volunteers across three continents to study the safety and efficacy of a single vaccine dose of JNJ-78436735 versus placebo.
      Contract Pharma Staff 09.23.20


    • Breaking News | Excipients | Industry News
      Hovione to Support Manufacture of Remdesivir for COVID-19

      Hovione to Support Manufacture of Remdesivir for COVID-19

      To meet Captisol demand associated with Remdesivir, Hovione will be producing per month the quantity it usually produces in one year.
      Contract Pharma Staff 09.23.20

    • Breaking News | Clinical Trials | Drug Development | Industry News
      ARCA Submits IND for AB201 in COVID-19

      ARCA Submits IND for AB201 in COVID-19

      AB201, a Phase IIb-ready recombinant protein aims to address the pathologies caused by viral infections from multiple aspects.
      Contract Pharma Staff 09.21.20

    Loading, Please Wait..
    Trending
    • SpectronRx, RLS Partner To Boost Radiopharmaceutical Pipeline And Supply Chain
    • Samsung Biologics Accelerates Timeline Of New Fifth Plant
    • Biopharma Layoffs In 1Q23
    • Veeva Business Consulting Expands With New R&D Services
    • CRO Industry Trends & Challenges
    Breaking News
    • EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
    • RK Pharma to Receive $200M Investment from PAG
    • Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
    • TMC Expands Executive Team
    • Peli BioThermal Opens Cold Chain Network Station in Southern California
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Sempera Organics and Alkemist Labs Announce Partnership for Mushroom Testing
    Nektium Expands International Distribution Network for Botanical Extracts
    Kemin Receives Positive EFSA Opinion for BetaVia Pure, its Beta-Glucan Ingredient
    Coatings World

    Latest Breaking News From Coatings World

    PPG’s New Paint for a New Start Initiative to Beautify Schools Worldwide with Colorful Makeovers
    Powder Technology, Inc. Announces New Electrical Coating
    Michelman Chosen as Inaugural Recipient of Innovation Research Interchange (IRI) Excellence Award
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cue Health Nabs FDA's First De Novo Nod for an At-Home COVID Test
    ISO 13485:2016 Certification Granted to Boston BioProducts
    Paul Colvin Joins Ora Inc. as Chief Operating Officer
    Contract Pharma

    Latest Breaking News From Contract Pharma

    EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins
    RK Pharma to Receive $200M Investment from PAG
    Axol Bioscience, StrataStem Partner on ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Announces Second Edition of Beauty&You Brand Incubator Program
    GetHarley Raises $52 Million in Latest Funding Round
    Refillable Skincare Products Face Hurdles Despite Growing Sustainability Awareness
    Happi

    Latest Breaking News From Happi

    Carrière Frères Introduces Candle Refills as New Sustainability Initiative
    Gen Z Entrepreneur Introduces The Ashley Marie Collection for 4C Hair Types
    The Estée Lauder Companies Expands Beauty&You Competition for Indian Beauty Brands
    Ink World

    Latest Breaking News From Ink World

    Siegwerk’s Center of Excellence in France Receives Facelift
    Epson announces MakeTheSwitch Campaign
    Pigments Market to Reach $26,598 Million by 2022: AMR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mark Andy reports successful Low Migration Workshop
    Ryback and Ryback Consulting launches Machinery division
    TLMI launches 2023 award programs
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    The Honest Company to Exit Europe, Asia
    TechnoPlants to Exhibit at ITMA
    Andritz Buys 100% Stake in Dan-Web
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthobiologics Market to Top $10.3 Billion by 2030
    Artelon Granted U.S. FDA 510(k) Clearance for FlexBand, FlexPatch & FlexBand Plus
    Synergy Spine Solutions Completes Enrollment in IDE Clinical Trial
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    ASSA ABLOY Receives Clearance from Mexico for HHI Acquisition
    Christoph Ostermann Named Chairman of Heliatek‘s Advisory Board
    Flexible and Printed Electronics Represented at productronica 2023

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login